Special access is gaining momentum, with announcements expected in 2027! Eli Lilly (LLY.US) is approaching surgical-level efficacy with its next-generation weight loss drug, aiming to recreate the "weight loss miracle."

According to reports from various media sources citing informed individuals, following an application by another patient to begin treatment with this drug, leading U.S. healthcare company Eli Lilly (LLY.US) will allow more patients to apply for special access to its experimental weight loss drug, retatrutide.